Literature DB >> 28947246

Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.

Georgia Kasten1, Khatera Nouri1, Holger Grohganz1, Thomas Rades1, Korbinian Löbmann2.   

Abstract

The introduction of a highly water soluble amino acid as co-amorphous co-former has previously been shown to significantly improve the dissolution rate of poorly water soluble drugs. In this work, dry ball milling (DBM) and liquid assisted grinding (LAG) were used to prepare different physical forms of salts of indomethacin (IND) with the amino acid lysine (LYS), allowing the direct comparison of their solid-state properties to their in vitro performance. X-ray powder diffraction and Fourier-transformed infrared spectroscopy showed that DBM experiments led to the formation of a fully co-amorphous salt, while LAG resulted in a crystalline salt. Differential scanning calorimetry showed that the samples prepared by DBM had a single glass transition temperature (Tg) of approx. 100°C for the co-amorphous salt, while a new melting point (223°C) was obtained for the crystalline salt prepared by LAG. Intrinsic dissolution and powder dissolution studies demonstrated an increased dissolution rate of the drug in the co-amorphous salt compared to pure amorphous IND and also the crystalline drug-LYS salt. Furthermore, the co-amorphous IND-LYS salt presented long term physical stability in dry conditions at 25°C and 40°C. Overall, it has been shown that the co-amorphous form of a salt has a superior performance in comparison to a crystalline salt.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-amorphous salt; Crystalline salt; Dissolution; Kinetics; Physical stability; Solubility

Mesh:

Substances:

Year:  2017        PMID: 28947246     DOI: 10.1016/j.ijpharm.2017.09.063

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Recent Advances in Enhancement of Dissolution and Supersaturation of Poorly Water-Soluble Drug in Amorphous Pharmaceutical Solids: A Review.

Authors:  Qin Shi; Fang Li; Stacy Yeh; Sakib M Moinuddin; Junbo Xin; Jia Xu; Hao Chen; Bai Ling
Journal:  AAPS PharmSciTech       Date:  2021-12-10       Impact factor: 3.246

Review 2.  Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.

Authors:  Qin Shi; Yanan Wang; Sakib M Moinuddin; Xiaodong Feng; Fakhrul Ahsan
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

3.  Mechanistic study of the solubilization effect of basic amino acids on a poorly water-soluble drug.

Authors:  Mohammed Suleiman Alsalhi; Paul G Royall; Ka Lung Andrew Chan
Journal:  RSC Adv       Date:  2022-06-29       Impact factor: 4.036

Review 4.  Co-Amorphous Solid Dispersions for Solubility and Absorption Improvement of Drugs: Composition, Preparation, Characterization and Formulations for Oral Delivery.

Authors:  Anna Karagianni; Kyriakos Kachrimanis; Ioannis Nikolakakis
Journal:  Pharmaceutics       Date:  2018-07-19       Impact factor: 6.321

5.  Understanding Concomitant Physical and Chemical Transformations of Simvastatin During Dry Ball Milling.

Authors:  Dattatray Modhave; Isha Saraf; Anjali Karn; Amrit Paudel
Journal:  AAPS PharmSciTech       Date:  2020-05-21       Impact factor: 3.246

6.  Solid-State Characterization and Compatibility Studies of Penciclovir, Lysine Hydrochloride, and Pharmaceutical Excipients.

Authors:  Rafaela Z C Meira; Isabela F B Biscaia; Camila Nogueira; Fabio S Murakami; Larissa S Bernardi; Paulo R Oliveira
Journal:  Materials (Basel)       Date:  2019-09-27       Impact factor: 3.623

Review 7.  Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.

Authors:  Jingwen Liu; Holger Grohganz; Korbinian Löbmann; Thomas Rades; Nele-Johanna Hempel
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.